Fig. 1 · Structure

Documents & Downloads

NS6180

Cat. No. A12405 CAS 353262-04-1

K(Ca) 3.1 channel blocker

NS6180 is a novel potent and selective KCa3.1 channel inhibitor(IC50= 9 nM) prevents T-cell activation and inflammation.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

NS6180 Research Summary

This section summarizes 4 in vitro studies of NS6180 from 3 published references. In vitro models include NA-NK cells; activated NK-92 cell.

NS6180 In Vitro Studies

NS6180 did not affect NA-NK cell degranulation in the presence of K562 cells compared with the corresponding condition without potassium channel blockers. In activated NK-92 cells, NS6180 application yielded an apparent current reduction attributed to background (leak) current. In rat hippocampal slices with acetylcholine- and physostigmine-induced gamma oscillations, NS6180 had no significant effect on peak gamma power compared with time-matched controls without drug applications. Preincubation with NS6180 significantly reduced basal intracellular calcium levels in primary NK cells. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Unchanged degranulation in NA-NK cells

Cell-based study · NA-NK cells [1]

NA-NK cells were preincubated with NS6180 at 0.1 µM and 1 µM before addition of K562 cells. Degranulation was unaffected compared with cells exposed to K562 cells without potassium channel blockers.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CD107a expression levelsReported result NS6180 (0.1 and 1 µM), in the presence of K562 cells: did not affect the degranulation of NA-NK cells.[1]

Literature-Reported Treatment Conditions

Treatment concentration
0.1 µM and 1 µM
Exposure duration
30–45 min before addition of K562 cells; 4 hours later
Method
pre-incubated with channel blockers
Co-treatment
Other interventions in this design: K562 cells 1∶1 ratio. Compound effect isolated by the comparison: in the presence of K562 cells without potassium channel blockers.
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: NS6180

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Degranulation Assays (S37, S38); Results > KCa3.1 Blockade Increases the Degranulation of A-NK Cells and their Ability to Kill K562 Cells (S111); Figure 4 legend (S159)

CD107a expression levels: CD107a expression levels; comparator: in the presence of K562 cells without potassium channel blockers — Results > KCa3.1 Blockade Increases the Degranulation of A-NK Cells and their Ability to Kill K562 Cells (S111); Figure 4 legend (S159)

Apparent current reduction in activated NK cells

Cell-based study · activated NK-92 cell [2]

Typical record of K+ (Kv and KCa3.1) currents from an activated NK-92 cell. After the application of 300 nM of specific KCa3.1 blocker NS6180, instead of the expected 95% block at −150 mV, an apparent current reduction was by 83% only due to a significant background (leak) current.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
K+ (Kv and KCa3.1) currentscurrent reduction 300 nM NS6180, −150 mV: 83%[2]

Literature-Reported Treatment Conditions

Treatment concentration
300 nM
Method
bath perfusion
Vehicle
DMSO
Co-treatment
Other interventions in this design: IL-2 500 UI/mL; IL-15 0.3 ng/mL. Compound effect isolated by the comparison: The black trace is the control, green trace is after the application of 300 nM of specific KCa3.1 blocker NS6180..
Reported limits
Not stated in the sentences used: schedule.
Methods and source locations

Compound reported in the paper: NS6180

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Reagents (S3); 2. Materials and Methods > 2.4. Electrophysiology (S33); 2. Materials and Methods > 2.5. Activation of Primary NK and NK-92 Cells (S38); Figure A2 legend (S173, S175, S176)

K+ (Kv and KCa3.1) currents: K+ (Kv and KCa3.1) currents; comparator: The black trace is the control — Figure A2 legend (S173, S175, S176)

Unchanged gamma power in rat hippocampal slices

Cell-based study · CA3 region of rat hippocampal slices; Wistar rats of both sexes; n = 7, N = 3 [3]

Rat hippocampal slices with acetylcholine- and physostigmine-induced gamma oscillations were treated with 1 μM NS6180. Peak gamma power showed no significant effect compared with time-matched controls without drug applications.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
normalized peak power of hippocampal gamma oscillationsReported result NS6180 (1 μM) had no significant effect on peak gamma power (control: 1.315 ± 0.077, n = 13; NS6180: 1.293 ± 0.237, n = 7, p = 0.990; Figure 1E).[3]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
100 min after induction for 60 min
Co-treatment
Other interventions in this design: acetylcholine 10 μM; physostigmine 2 μM. Compound effect isolated by the comparison: time-matched control experiments without drug applications.
Reported limits
Not stated in the sentences used: route, vehicle. Removed after verification: value.
Methods and source locations

Compound reported in the paper: NS6180

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods and Materials > Animals and Slice Preparation (S3); Methods and Materials > Extracellular Recordings and Analysis (S14); Results > Activation of KCa2 Channels Inhibits and Blockade Increases Gamma Oscillations (S52, S58); Figure 1 legend (S87, S88)

normalized peak power of hippocampal gamma oscillations: normalized peak power of hippocampal gamma oscillations; comparator: time-matched control experiments without drug applications — Results > Activation of KCa2 Channels Inhibits and Blockade Increases Gamma Oscillations (S58); Figure 1 legend (S87)

Reduced basal calcium levels in primary NK cells

Cell-based study · primary NK cells [2]

Primary NK cells were preincubated with NS6180 at 1 and 10 μM for 20 min. Treatment induced a significant reduction in basal intracellular calcium levels.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
basal [Ca2+]i levelsReported result 1 and 10 μM NS6180: Preincubation with KCa3.1 specific blocker NS6180 induced a significant reduction in basal [Ca2+]i levels in primary NK cells.[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 and 10 μM
Exposure duration
20 min
Method
preincubated with the blocker
Vehicle
DMSO
Reported limits
Not stated in the sentences used: control.
Methods and source locations

Compound reported in the paper: NS6180

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

2. Materials and Methods > 2.1. Reagents (S3); 2. Materials and Methods > 2.7. Intracellular Ca2+ Measurements (S51, S52, S60); 3. Results > 3.2. Effect of KCa3.1 Block on Intracellular Ca2+ Dynamics in NK Cells and NK-92 Cell Line > 3.2.1. KCa 3.1 Controls Basal [Ca2+]i Level in Resting NK Cells (S115, S117)

basal [Ca2+]i levels: basal [Ca2+]i levels — 3. Results > 3.2. Effect of KCa3.1 Block on Intracellular Ca2+ Dynamics in NK Cells and NK-92 Cell Line > 3.2.1. KCa 3.1 Controls Basal [Ca2+]i Level in Resting NK Cells (S115, S117)

Specifications

Manufacturer Adooq Bioscience
Actions Blocker
CAS Number 353262-04-1
Applications K(Ca) 3.1 channel blocker
Formula C16H12F3NOS
Molecular Weight 323.33
SMILES
FC(F)(C1=CC(CN2C3=CC=CC=C3SCC2=O)=CC=C1)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

NS6180 Research References

  1. [1] Koshy S, Wu D, Hu X, et al. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. PLoS One (2013). PMID: 24146918 DOI: 10.1371/journal.pone.0076740 Source material
  2. [2] Olivas-Aguirre M, Cruz-Aguilar LH, Pottosin I, et al. Reduction of Ca2+ Entry by a Specific Block of KCa3.1 Channels Optimizes Cytotoxic Activity of NK Cells against T-ALL Jurkat Cells. Cells (2023). PMID: 37626875 DOI: 10.3390/cells12162065 Source material
  3. [3] Klemz A, Wildner F, Tütüncü E, et al. Regulation of Hippocampal Gamma Oscillations by Modulation of Intrinsic Neuronal Excitability. Front Neural Circuits (2021). PMID: 35177966 DOI: 10.3389/fncir.2021.778022 Source material

Added to your cart

View Cart Checkout
Loading...